Amgen Inc. Files 8-K for Operations and Financials

Ticker: AMGN · Form: 8-K · Filed: 2024-08-06T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: AMGN

TL;DR

Amgen filed an 8-K on Aug 6th, expect financial and operational updates soon.

AI Summary

On August 6, 2024, Amgen Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details but serves as a notification of these disclosures.

Why It Matters

This filing indicates that Amgen Inc. is providing updates on its financial performance and operational status to the SEC and the public.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new material financial information or strategic changes.

Key Players & Entities

FAQ

What specific financial information is being disclosed in this 8-K filing?

This 8-K filing, dated August 6, 2024, indicates that Amgen Inc. is reporting on its Results of Operations and Financial Condition and providing Financial Statements and Exhibits, but the document itself does not contain the specific financial figures.

What is the purpose of this 8-K filing for Amgen Inc.?

The purpose of this 8-K filing is to report current information regarding Amgen Inc.'s results of operations and financial condition, as well as to file financial statements and exhibits.

When was this 8-K report filed by Amgen Inc.?

Amgen Inc. filed this 8-K report on August 6, 2024.

Where is Amgen Inc.'s principal executive office located?

Amgen Inc.'s principal executive offices are located at One Amgen Center Drive, Thousand Oaks, California, 91320-1799.

What is Amgen Inc.'s state of incorporation?

Amgen Inc. is incorporated in Delaware.

From the Filing

0000318154-24-000033.txt : 20240806 0000318154-24-000033.hdr.sgml : 20240806 20240806160506 ACCESSION NUMBER: 0000318154-24-000033 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240806 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 241179084 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 amgn-20240806.htm 8-K amgn-20240806 0000318154 false 0000318154 2024-08-06 2024-08-06 0000318154 exch:XNGS us-gaap:CommonStockMember 2024-08-06 2024-08-06 0000318154 amgn:A2.00SeniorNotesDue2026Member exch:XNGS 2024-08-06 2024-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2024  - Amgen Inc. (Exact name of registrant as specified in its charter)    Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive   Thousand Oaks California 91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code ( 805 ) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value AMGN The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026 AMGN26 The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. Second Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On August 6, 2024 , the Company issued a press release announcing its unaudited results of operations for the three and six months ended June 30, 2024, and its unaudited financial position as of June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G prom

View on Read The Filing